Crinetics Pharmaceuticals, Inc

(NASDAQ:CRNX)

Latest On Crinetics Pharmaceuticals, Inc (CRNX):

Date/Time Type Description Signal Details
2023-05-25 19:43 ESTNewsCrinetics Pharmaceuticals And Its Value Proposition In AcromegalyN/A
2023-05-04 23:54 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.85 misses by $0.01, revenue of $2.67M beats by $2.43MN/A
2023-03-06 12:48 ESTNewsEvaluating Crinetics' Oral Long Shot For AcromegalyN/A
2023-02-28 18:44 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.84 misses by $0.01, revenue of $0.71M beats by $0.41MN/A
2022-12-30 22:15 ESTNewsCrinetics: FY23 Could Be Turning Point With Two Phase 3 Acromegaly ReadoutsN/A
2022-11-29 04:07 ESTNewsCrinetics says FDA didn’t clear Phase 2 study request for hyperinsulinism drugN/A
2022-11-15 00:39 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.78 beats by $0.03, revenue of $0.46M beats by $0.26MN/A
2022-08-12 17:31 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28MN/A
2022-06-13 22:31 ESTNewsCrinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection PointN/A
2022-05-25 15:30 ESTNewsCrinetics hormone CRN04894 therapy shows promise in early-stage studyN/A
2022-05-13 09:56 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.73 misses by $0.17, revenue of $3.13M misses by $2.07MN/A
2022-04-29 23:10 ESTNewsCrinetics: An Orphan Disease Innovator On The RiseN/A
2022-04-24 11:40 ESTNewsCrinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes ProgressN/A
2022-04-13 16:17 ESTNewsCrinetics Pharmaceuticals prices $125M stock offeringN/A
2022-04-01 04:52 ESTNewsCrinetics stock gains on hyperinsulinism candidate's trial data; JMP raises PTN/A
2022-03-31 09:08 ESTNewsCrinetics Pharmaceuticals reports resultsN/A
2022-03-30 16:39 ESTNewsCrinetics shows dose-dependent effect of hyperinsulinism candidate in early trialN/A
2022-03-18 16:25 ESTNewsCrinetics delays early Phase 1 data for experimental therapy due to COVID-19N/A
2022-02-28 09:07 ESTNewsCrinetics, Sanwa ink licensing deal for cancer/hormonal disorder drug in JapanN/A
2021-10-22 05:14 ESTNewsCrinetics Pharmaceuticals prices $150M in stock offeringN/A
2021-10-21 03:29 ESTNewsCrinetics drops after announcing common stock offeringN/A
2021-09-21 15:29 ESTNewsCrinetics posts preliminary results from early-stage CRN04777 hyperinsulinism studyN/A
2021-09-21 15:23 ESTNewsCrinetics Pharmaceuticals (CRNX) Investor Presentation - SlideshowN/A
2021-09-02 17:30 ESTNewsCrinetics Pharmaceuticals names Jeff Knight as chief operating officerN/A
2021-08-10 23:06 ESTNewsCrinetics Pharmaceuticals posts positive data from early-stage CRN04894 trialN/A
2021-08-10 23:05 ESTNewsCrinetics Pharmaceuticals EPS misses by $0.10N/A
2021-07-29 16:43 ESTNewsCrinetics Pharmaceuticals proposes $15M in private placement with Frazier HealthcareN/A
2021-07-21 02:52 ESTNewsCrinetics doses first patient in late-stage oral paltusotine acromegaly trialN/A
2021-05-07 06:27 ESTNewsCrinetics Pharmaceuticals EPS misses by $0.04N/A
2021-04-08 07:33 ESTNewsCrinetics Pharma raises $75M via equity offeringN/A
2021-03-30 23:41 ESTNewsCrinetics Pharmaceuticals, Inc. (CRNX) CEO Scott Struthers on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-30 23:41 ESTNewsCrinetics Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call PresentationN/A
2021-01-23 04:21 ESTNewsCrinetics Pharmaceuticals (CRNX) Presents At 39th Annual J.P. Morgan Healthcare Conference - SlideshowN/A
2020-12-13 03:42 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 07:37 ESTAnalyst RatingThe Analyst Target Price has increased from $32.8 to $33.6.Buy
2020-11-09 11:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 11:40 ESTEarnings EstimateAn EPS average of -$0.59 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-07 15:30 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 06:16 ESTNewsCrinetics Pharmaceuticals EPS misses by $0.03N/A
2020-10-30 12:37 ESTAnalyst RatingThe Analyst Target Price has decreased from $36.75 to $32.8.Neutral
2020-10-26 14:41 ESTNewsCrinetics Pharma lead drug successful in mid-stage acromegaly studyN/A
2020-09-26 12:27 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 04:35 ESTFinancialsCompany financials have been released.Neutral
2020-09-08 04:25 ESTAnalyst RatingThe Analyst Target Price has decreased from $36.8 to $36.75.Neutral
2020-09-05 01:11 ESTNewsCrinetics Pharma to advance ACTH antagonist candidate into the clinicN/A
2020-09-05 00:31 ESTFinancialsCompany financials have been released.Neutral
2020-09-02 11:29 ESTNewsCrinetics Pharmaceuticals- Superior Molecules In EndocrinologyN/A
2020-08-09 08:28 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 16:03 ESTNewsCrinetics Pharmaceuticals EPS beats by $0.02N/A
2020-07-31 00:39 ESTFinancialsCompany financials have been released.Neutral

About Crinetics Pharmaceuticals, Inc (CRNX):

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

CRNX Quotes by TradingView

See Advanced Chart

General

  • Name Crinetics Pharmaceuticals, Inc
  • Symbol CRNX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 68
  • Fiscal Year EndDecember
  • IPO Date2018-07-18
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.crinetics.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 1102.47
  • Price/Book (Most Recent Quarter) 2.99
  • Enterprise Value Revenue 961.96
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.55
  • Operating Margin -17443%
  • Return on Assets -25%
  • Return on Equity -42%
  • Revenue 392000
  • Earnings Per Share -$1.62
  • Revenue Per Share $0.01
  • Gross Profit -40313000
  • Quarterly Earnings Growth -80.7%
View More

Highlights

  • Market Capitalization 531.37 million
  • EBITDA -40113000
  • PE Ratio -16.43
  • Analyst Target Price $33.6
  • Book Value Per Share $5.69
View More

Share Statistics

  • Shares Outstanding 32.92 million
  • Shares Float 20.69 million
  • % Held by Insiders 450%
  • % Held by Institutions 95.14%
  • Shares Short 1.53 million
  • Shares Short Prior Month 1.38 million
  • Short Ratio 13.29
  • Short % of Float 6%
  • Short % of Shares Outstanding 5%
View More

Technicals

  • Beta 1.23
  • 52 Week High $23.7
  • 52 Week Low $11.61
  • 50 Day Moving Average 15.77
  • 200 Day Moving Average 14.69
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Crinetics Pharmaceuticals, Inc (CRNX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Crinetics Pharmaceuticals, Inc (CRNX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-06$N/A-$0.56-$0.53-6.38%
2020-06-302020-08-07$N/A-$0.53-$0.554.21%
2020-03-312020-05-08$N/A-$0.71-$0.63-12.66%
2019-12-312020-03-09$321000-$0.60-$0.6811.35%
2019-09-302019-11-12$505000-$0.60-$0.54-11.92%
2019-06-302019-08-13$N/A-$0.51-$0.46-11.79%
2019-03-312019-05-13$367000-$0.37-$0.394.61%
2018-12-312019-03-13$781000-$0.35-$0.4115.09%
2018-09-302018-11-13$548000-$0.38-$0.34-10.47%
2018-06-302018-08-30$657000-$0.33-$0.31-7.32%

Crinetics Pharmaceuticals, Inc (CRNX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A N/A N/A 11.82 million
Income Before Tax N/A N/A N/A -14.55 million -14.43 million
Selling General Administrative N/A N/A N/A 3.39 million 3.91 million
Gross Profit N/A N/A N/A -11.82 million 505000
Ebit N/A N/A N/A -15.21 million -15.23 million
Operating Income N/A N/A N/A -15.21 million -15.23 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A 321000 505000
Cost of Revenue N/A N/A N/A 12.14 million N/A
Total Other Income Expense Net N/A N/A N/A 665000 799000
Net Income From Continuing Operations N/A N/A N/A -14.55 million -14.43 million
Net Income Applicable to Common Shares -18.32 million -16.49 million -17.36 million -14.55 million -14.43 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A -12.8 million 20.45 million
Change to Liabilities -752000 -831000 2.39 million 674000 114000
Total Cash Flow from Investing Activities -24.83 million 17.6 million 16.34 million -12.82 million 20.45 million
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A 17000 22000
Change to Operating Activities -2.04 million -1.25 million 491000 -1.47 million -1.11 million
Change in Cash N/A N/A N/A -26.25 million 6.86 million
Total Cash from Operating Activities -18 million -15.86 million -12.23 million -13.45 million -13.61 million
Depreciation N/A N/A N/A 229000 228000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 2.86 million 2.48 million 2.01 million 1.66 million 1.59 million
Capital Expenditures N/A N/A N/A 28000 N/A
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A N/A 13.24 million 12.99 million
Total Stockholder Equity N/A N/A N/A 117.14 million 129.52 million
Other Current Liabilities 810000 N/A N/A N/A N/A
Total Assets N/A N/A N/A 130.38 million 142.51 million
Common Stock 333.15 million 330.3 million 219.43 million 210.79 million 208.58 million
Other Current Assets N/A N/A N/A 2.48 million N/A
Retained Earnings -145.97 million -127.65 million -111.16 million -93.8 million -79.25 million
Other Liabilities 28000 34000 39000 49000 60000
Other Assets 500000 500000 500000 582000 500000
Cash N/A N/A N/A 40.33 million 66.58 million
Total Current Liabilities 8.83 million N/A N/A 8.34 million 7.88 million
Other Stockholder Equity 44000 127000 167000 148000 198000
Property, Plant & Equipment 5.7 million 6.01 million 6.22 million 6.46 million 6.61 million
Total Current Assets 194.12 million N/A N/A 123.34 million 135.4 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 187.22 million 202.77 million 108.44 million 117.14 million 129.52 million
Short Term Investments N/A N/A N/A 78.07 million 65.09 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 4.69 million N/A N/A 2.7 million 2.11 million

Crinetics Pharmaceuticals, Inc (CRNX) Chart:

Crinetics Pharmaceuticals, Inc (CRNX) News:

Below you will find a list of latest news for Crinetics Pharmaceuticals, Inc (CRNX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Crinetics Pharmaceuticals, Inc (CRNX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-06-18200CALL0 00TRUE00
2026-06-18250CALL0 979.04TRUE00
2026-06-18303.8CALL0 4556.92TRUE00
2026-06-18340CALL0 273.87FALSE00
2026-06-18351CALL0 458.62FALSE00
2026-06-18361.9CALL0 353.31FALSE00
2026-06-18370.7CALL0 16699.78FALSE00
2026-06-18380CALL0 15106.86FALSE00
2026-06-18390CALL0 39113.04FALSE00
2026-06-18402.11CALL0 206119.59FALSE00
2026-06-18410CALL0 0126.71FALSE00
2026-06-18420CALL0 8134.59FALSE00
2026-06-18430CALL0 27142.09FALSE00
2026-06-18440CALL0 2149.27FALSE00
2026-06-18450CALL0 214135.32FALSE00
2026-06-18460CALL0 1162.76FALSE00
2026-06-18470CALL0 0169.12FALSE00
2026-06-18480CALL0 9175.26FALSE00
2026-06-18490CALL0 0181.18FALSE00
2026-06-18500CALL0 57186.92FALSE00
2026-06-18550CALL0 13213.07FALSE00
2026-06-18600CALL0 28235.85FALSE00
2026-06-18650CALL0 28159.37FALSE00
2026-06-18700CALL0 20274.17FALSE00
2026-06-18750CALL0 40290.61FALSE00
2026-06-18800CALL0 26244.4FALSE00
2026-06-18850CALL0 0319.51FALSE00
2026-06-18200PUT0 0250.29FALSE00
2026-06-18250.1PUT10 8170.34FALSE0.10
2026-06-18300.85PUT0 13865.55FALSE00
2026-06-18340PUT0 6263.01TRUE00
2026-06-18350PUT0 11357.03TRUE00
2026-06-18360PUT0 2457.33TRUE00
2026-06-18370PUT0 961.99TRUE00
2026-06-18380PUT0 2566.41TRUE00
2026-06-18390PUT0 859.79TRUE00
2026-06-18400PUT0 670.86TRUE00
2026-06-18410PUT0 067.36TRUE00
2026-06-18420PUT0 578.87TRUE00
2026-06-18430PUT0 284.7TRUE00
2026-06-18440PUT0 1090.3TRUE00
2026-06-184511.7PUT0 5480.63TRUE00
2026-06-18460PUT0 0100.92TRUE00
2026-06-18470PUT0 00TRUE00
2026-06-18480PUT0 10TRUE00
2026-06-18490PUT0 0115.61TRUE00
2026-06-18500PUT0 0120.22TRUE00
2026-06-18550PUT0 0141.49TRUE00
2026-06-18600PUT0 0160.34TRUE00
2026-06-18650PUT0 00TRUE00
2026-06-18700PUT0 0192.67TRUE00
2026-06-18750PUT0 0206.79TRUE00
2026-06-18800PUT0 0219.83TRUE00
2026-06-18850PUT0 0231.96TRUE00
2026-07-17250CALL0 084.98TRUE00
2026-07-17260CALL0 076.57TRUE00
2026-07-17270CALL0 075.25TRUE00
2026-07-17280CALL0 071.36TRUE00
2026-07-17290CALL0 068.26TRUE00
2026-07-17305.06CALL0 564.99TRUE00
2026-07-17310CALL0 064.47TRUE00
2026-07-17320CALL0 065TRUE00
2026-07-17330CALL0 064.84TRUE00
2026-07-17340CALL0 065.15FALSE00
2026-07-17350CALL0 062.71FALSE00
2026-07-17360CALL0 064.72FALSE00
2026-07-17371.73CALL0 173.29FALSE00
2026-07-17380CALL0 072.06FALSE00
2026-07-17390CALL0 075.44FALSE00
2026-07-17401.33CALL0 5667.87FALSE00
2026-07-17410CALL0 081.48FALSE00
2026-07-17420CALL0 084.92FALSE00
2026-07-17430CALL0 088.08FALSE00
2026-07-17440CALL0 091.68FALSE00
2026-07-17450CALL0 794.34FALSE00
2026-07-17500CALL0 6110.26FALSE00
2026-07-17550CALL0 0124.79FALSE00
2026-07-17250PUT0 0113.82FALSE00
2026-07-17260PUT0 0105.56FALSE00
2026-07-17270PUT0 097.35FALSE00
2026-07-17280PUT0 084.89FALSE00
2026-07-17290PUT0 079.52FALSE00
2026-07-17300PUT0 071.18FALSE00
2026-07-17310PUT0 070.33FALSE00
2026-07-17320PUT0 5066.69FALSE00
2026-07-17330PUT0 065.43FALSE00
2026-07-17340PUT0 3464.15TRUE00
2026-07-17350PUT0 061.18TRUE00
2026-07-17360PUT0 3060.92TRUE00
2026-07-17370PUT0 060.71TRUE00
2026-07-17380PUT0 058.09TRUE00
2026-07-17390PUT0 060.91TRUE00
2026-07-17400PUT0 060.2TRUE00
2026-07-17410PUT0 061.67TRUE00
2026-07-17420PUT0 062.51TRUE00
2026-07-17430PUT0 062.67TRUE00
2026-07-17440PUT0 059.42TRUE00
2026-07-17450PUT0 065.47TRUE00
2026-07-17500PUT0 071.29TRUE00
2026-07-17550PUT0 00TRUE00
2026-09-18200CALL0 265.55TRUE00
2026-09-18259.8CALL1 081.25TRUE9.80
2026-09-18300CALL0 1266.65TRUE00
2026-09-18350CALL0 065.34FALSE00
2026-09-18402.8CALL0 6559.14FALSE00
2026-09-18451.59CALL0 2259.77FALSE00
2026-09-18500CALL0 2575.91FALSE00
2026-09-18550CALL0 4868.53FALSE00
2026-09-18600CALL0 490.22FALSE00
2026-09-18650CALL0 496.77FALSE00
2026-09-18700CALL0 1103.03FALSE00
2026-09-18750CALL0 0108.62FALSE00
2026-09-18800CALL0 1114.28FALSE00
2026-09-18850CALL0 0118.84FALSE00
2026-09-18200PUT0 1199.41FALSE00
2026-09-18251.5PUT0 15176.02FALSE00
2026-09-18300PUT0 765.77FALSE00
2026-09-18350PUT0 4064.67TRUE00
2026-09-18400PUT0 5160.17TRUE00
2026-09-18450PUT0 260.57TRUE00
2026-09-18500PUT0 062.5TRUE00
2026-09-18550PUT0 064.28TRUE00
2026-09-18600PUT0 067.76TRUE00
2026-09-18650PUT0 177.77TRUE00
2026-09-18700PUT0 084.54TRUE00
2026-09-18750PUT0 090.75TRUE00
2026-09-18800PUT0 096.49TRUE00
2026-09-18850PUT0 0101.86TRUE00
2026-12-18200CALL0 365.58TRUE00
2026-12-18250CALL0 061.85TRUE00
2026-12-18300CALL0 062.26TRUE00
2026-12-18320CALL0 061.13TRUE00
2026-12-18330CALL0 060.45TRUE00
2026-12-18340CALL0 060.03FALSE00
2026-12-18350CALL0 059.89FALSE00
2026-12-18360CALL0 459.49FALSE00
2026-12-18370CALL0 058.87FALSE00
2026-12-18380CALL0 058.27FALSE00
2026-12-18390CALL0 057.97FALSE00
2026-12-18400CALL0 1251.12FALSE00
2026-12-18410CALL0 256.18FALSE00
2026-12-18420CALL0 055.48FALSE00
2026-12-18430CALL0 055.12FALSE00
2026-12-18440CALL0 056.25FALSE00
2026-12-18450CALL0 354.06FALSE00
2026-12-18460CALL0 154.89FALSE00
2026-12-18472.45CALL0 155.29FALSE00
2026-12-18482.25CALL0 152.63FALSE00
2026-12-18500CALL0 2958.04FALSE00
2026-12-18550CALL0 662.2FALSE00
2026-12-18600CALL0 766.81FALSE00
2026-12-18200PUT0 078.82FALSE00
2026-12-18250PUT0 163.44FALSE00
2026-12-18300PUT0 060.63FALSE00
2026-12-18320PUT0 060.17FALSE00
2026-12-18330PUT0 059.91FALSE00
2026-12-18340PUT0 059.63TRUE00
2026-12-18350PUT0 3553.38TRUE00
2026-12-18360PUT0 058.81TRUE00
2026-12-18370PUT0 058.28TRUE00
2026-12-18380PUT0 058.03TRUE00
2026-12-18390PUT0 057.01TRUE00
2026-12-18400PUT0 056.81TRUE00
2026-12-18410PUT0 056.39TRUE00
2026-12-18420PUT0 055.72TRUE00
2026-12-18430PUT0 054.23TRUE00
2026-12-18440PUT0 054.83TRUE00
2026-12-184513.05PUT0 4055.87TRUE00
2026-12-18460PUT0 053.58TRUE00
2026-12-18470PUT0 054.25TRUE00
2026-12-18480PUT0 1055.5TRUE00
2026-12-18500PUT0 053.17TRUE00
2026-12-18550PUT0 053.12TRUE00
2026-12-18600PUT0 056.88TRUE00

Latest CRNX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST5$17.17
Jun 13, 2022 7:59 PM EST100$17.19
Jun 13, 2022 7:59 PM EST1$17.17
Jun 13, 2022 7:59 PM EST100$17.2
Jun 13, 2022 7:59 PM EST100$17.2

Crinetics Pharmaceuticals, Inc (CRNX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038179/0001209191-20-038179-index.htm
2018-07-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1658247/000000000018021079/0000000000-18-021079-index.htm
2019-08-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1658247/000000000019012560/0000000000-19-012560-index.htm
2018-09-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000031506618002299/0000315066-18-002299-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000031506619000968/0000315066-19-000968-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000031506620000861/0000315066-20-000861-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019963/0000899243-18-019963-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019964/0000899243-18-019964-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019965/0000899243-18-019965-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019967/0000899243-18-019967-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019968/0000899243-18-019968-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019972/0000899243-18-019972-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019974/0000899243-18-019974-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019975/0000899243-18-019975-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019978/0000899243-18-019978-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019979/0000899243-18-019979-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318020264/0000899243-18-020264-index.htm
2019-02-125Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924319003318/0000899243-19-003318-index.htm
2019-02-125Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924319003326/0000899243-19-003326-index.htm
2020-04-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924320010940/0000899243-20-010940-index.htm
2018-07-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000094787118000610/0000947871-18-000610-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000101297518000919/0001012975-18-000919-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000101297518000925/0001012975-18-000925-index.htm
2018-08-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000101297518001046/0001012975-18-001046-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918045567/0001104659-18-045567-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918045579/0001104659-18-045579-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918046292/0001104659-18-046292-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918046330/0001104659-18-046330-index.htm
2018-07-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918048071/0001104659-18-048071-index.htm
2019-01-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919003219/0001104659-19-003219-index.htm
2019-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919006113/0001104659-19-006113-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919008632/0001104659-19-008632-index.htm
2019-02-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919010154/0001104659-19-010154-index.htm
2019-03-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919016338/0001104659-19-016338-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919037468/0001104659-19-037468-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000110465920011470/0001104659-20-011470-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000110465920021136/0001104659-20-021136-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000114420419008307/0001144204-19-008307-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000117266120000650/0001172661-20-000650-index.htm
2018-07-128-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1658247/000119312518216421/0001193125-18-216421-index.htm
2018-07-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1658247/000119312518217820/0001193125-18-217820-index.htm
2018-07-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1658247/000119312518217824/0001193125-18-217824-index.htm
2018-07-17S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1658247/000119312518219860/0001193125-18-219860-index.htm
2018-07-18424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1658247/000119312518220701/0001193125-18-220701-index.htm
2018-07-18S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1658247/000119312518220704/0001193125-18-220704-index.htm
2018-07-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312518222517/0001193125-18-222517-index.htm
2018-07-30SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1658247/000119312518231543/0001193125-18-231543-index.htm
2018-08-28SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1658247/000119312518259557/0001193125-18-259557-index.htm
2018-08-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312518263610/0001193125-18-263610-index.htm
2018-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312518289506/0001193125-18-289506-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312518325476/0001193125-18-325476-index.htm
2019-08-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1658247/000119312519220012/0001193125-19-220012-index.htm
2019-08-19S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1658247/000119312519224488/0001193125-19-224488-index.htm
2019-08-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1658247/000119312519224495/0001193125-19-224495-index.htm
2019-08-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1658247/000119312519230761/0001193125-19-230761-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312520099551/0001193125-20-099551-index.htm
2020-04-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1658247/000119312520107151/0001193125-20-107151-index.htm
2020-04-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312520107156/0001193125-20-107156-index.htm
2020-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312520108092/0001193125-20-108092-index.htm
2020-04-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1658247/000119312520108096/0001193125-20-108096-index.htm
2020-04-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1658247/000119312520111625/0001193125-20-111625-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119018982/0001209191-19-018982-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119018983/0001209191-19-018983-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119018984/0001209191-19-018984-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038894/0001209191-19-038894-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038896/0001209191-19-038896-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038897/0001209191-19-038897-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038902/0001209191-19-038902-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038905/0001209191-19-038905-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119042285/0001209191-19-042285-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119042286/0001209191-19-042286-index.htm
2019-08-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119045039/0001209191-19-045039-index.htm
2019-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119061184/0001209191-19-061184-index.htm
2020-02-115Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120008269/0001209191-20-008269-index.htm
2020-02-115Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120008272/0001209191-20-008272-index.htm
2020-02-115Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120008280/0001209191-20-008280-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120012974/0001209191-20-012974-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120012987/0001209191-20-012987-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120012997/0001209191-20-012997-index.htm
2020-03-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120021372/0001209191-20-021372-index.htm
2020-04-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120026196/0001209191-20-026196-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038153/0001209191-20-038153-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038161/0001209191-20-038161-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038166/0001209191-20-038166-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038172/0001209191-20-038172-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038179/0001209191-20-038179-index.htm
2020-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120042897/0001209191-20-042897-index.htm
2020-09-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120049508/0001209191-20-049508-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120049518/0001209191-20-049518-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020002831/0001213900-20-002831-index.htm
2020-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020003601/0001213900-20-003601-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020006030/0001213900-20-006030-index.htm
2020-04-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2020-06-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020014709/0001213900-20-014709-index.htm
2018-07-12CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1658247/000135445718000250/0001354457-18-000250-index.htm
2018-08-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459018022504/0001564590-18-022504-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459018029304/0001564590-18-029304-index.htm
2019-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019007555/0001564590-19-007555-index.htm
2019-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1658247/000156459019007561/0001564590-19-007561-index.htm
2019-04-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019011511/0001564590-19-011511-index.htm
2019-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1658247/000156459019013719/0001564590-19-013719-index.htm
2019-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1658247/000156459019013723/0001564590-19-013723-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019018827/0001564590-19-018827-index.htm
2019-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459019018831/0001564590-19-018831-index.htm
2019-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019023431/0001564590-19-023431-index.htm
2019-07-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019025016/0001564590-19-025016-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019031797/0001564590-19-031797-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459019031801/0001564590-19-031801-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019042893/0001564590-19-042893-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459019042900/0001564590-19-042900-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000156459020004205/0001564590-20-004205-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020009362/0001564590-20-009362-index.htm
2020-03-0910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1658247/000156459020009365/0001564590-20-009365-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1658247/000156459020019202/0001564590-20-019202-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1658247/000156459020019210/0001564590-20-019210-index.htm
2020-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020023260/0001564590-20-023260-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459020023265/0001564590-20-023265-index.htm
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020030117/0001564590-20-030117-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020038067/0001564590-20-038067-index.htm
2020-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459020038069/0001564590-20-038069-index.htm
2020-09-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020042431/0001564590-20-042431-index.htm
2020-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020044046/0001564590-20-044046-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020047499/0001564590-20-047499-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020051684/0001564590-20-051684-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459020051686/0001564590-20-051686-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000161577418006600/0001615774-18-006600-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2018-07-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000161577418006903/0001615774-18-006903-index.htm
2019-03-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000161577419004434/0001615774-19-004434-index.htm
2018-07-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1658247/999999999518001811/9999999995-18-001811-index.htm
2019-08-29EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1658247/999999999519002011/9999999995-19-002011-index.htm

Crinetics Pharmaceuticals, Inc (CRNX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Crinetics Pharmaceuticals, Inc (CRNX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 450%
Institutional Ownership: 9514%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-03-185AM Ventures IV, L.P.10% Share HolderSell6,194.0024.25150,208.84104,489.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919016338/0001104659-19-016338-index.htm
2019-08-05Richard Scott StruthersPresident & CEOBuy10,000.001.9119,100.001,225,805.00https://www.sec.gov/Archives/edgar/data/1658247/000120919119045039/0001209191-19-045039-index.htm
2019-12-16Matthew K FustDirectorSell3,500.0022.5078,750.0012,536.00https://www.sec.gov/Archives/edgar/data/1658247/000120919119061184/0001209191-19-061184-index.htm
2019-01-225AM Ventures IV, L.P.10% Share HolderSell10,486.0021.88229,381.25129,483.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919003219/0001104659-19-003219-index.htm
2018-07-205AM Ventures IV, L.P.10% Share HolderBuy4,600.0017.0078,200.00139,969.00https://www.sec.gov/Archives/edgar/data/1658247/000110465918046330/0001104659-18-046330-index.htm
2018-07-20Vivo Capital VIII, LLC10% Share HolderBuy141,177.0017.002,400,009.00141,177.00https://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2019-12-16Matthew K FustDirectorBuy3,500.001.916,685.0016,036.00https://www.sec.gov/Archives/edgar/data/1658247/000120919119061184/0001209191-19-061184-index.htm
2020-03-09Vivo Capital VIII, LLC10% Share HolderSell133.0019.502,593.50168,165.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020006030/0001213900-20-006030-index.htm
2020-02-10Vivo Capital VIII, LLC10% Share HolderSell5,904.0021.40126,345.60168,298.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-07Vivo Capital VIII, LLC10% Share HolderSell4,614.0022.00101,508.00174,202.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-04Vivo Capital VIII, LLC10% Share HolderSell10,519.0022.80239,833.20178,816.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002831/0001213900-20-002831-index.htm
2020-01-31Vivo Capital VIII, LLC10% Share HolderSell4,220.0021.7091,574.00189,335.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-30Vivo Capital VIII, LLC10% Share HolderSell5,940.0022.10131,274.00193,555.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-29Vivo Capital VIII, LLC10% Share HolderSell10,878.0022.20241,491.60199,495.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2018-07-20Alan Seth KrasnerChief Medical OfficerBuy2,000.0017.0034,000.002,000.00https://www.sec.gov/Archives/edgar/data/1658247/000089924318020264/0000899243-18-020264-index.htm
2019-03-20Vivo Capital VIII, LLC10% Share HolderSell83,984.0022.251,868,644.00210,373.00https://www.sec.gov/Archives/edgar/data/1658247/000161577419004434/0001615774-19-004434-index.htm
2020-04-17Vivo Capital VIII, LLC10% Share HolderSell74,333.0015.401,144,728.202,162,587.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2020-04-16Vivo Capital VIII, LLC10% Share HolderSell26,527.0015.20403,210.402,236,920.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2020-04-15Vivo Capital VIII, LLC10% Share HolderSell189,625.0015.502,939,187.502,263,447.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2019-06-215AM Ventures IV, L.P.InsiderSell240,000.0022.205,328,000.002,267,797.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919037468/0001104659-19-037468-index.htm
2018-07-20PERCEPTIVE ADVISORS LLCDirectorBuy400,000.0017.006,800,000.002,280,305.00https://www.sec.gov/Archives/edgar/data/1658247/000101297518000925/0001012975-18-000925-index.htm
2020-04-07Vivo Capital VIII, LLC10% Share HolderSell5,373.0014.2076,296.602,453,072.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2020-04-03Vivo Capital VIII, LLC10% Share HolderSell263,600.0013.803,637,680.002,458,445.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2019-03-185AM Ventures IV, L.P.10% Share HolderSell148,645.0024.253,604,745.302,507,797.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919016338/0001104659-19-016338-index.htm
2020-03-09Vivo Capital VIII, LLC10% Share HolderSell347.0019.506,766.502,722,045.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020006030/0001213900-20-006030-index.htm
2020-02-10Vivo Capital VIII, LLC10% Share HolderSell1,451.0021.4031,051.402,722,392.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-07Vivo Capital VIII, LLC10% Share HolderSell1,134.0022.0024,948.002,723,843.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-04Vivo Capital VIII, LLC10% Share HolderSell2,584.0022.8058,915.202,724,977.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002831/0001213900-20-002831-index.htm
2020-01-31Vivo Capital VIII, LLC10% Share HolderSell1,037.0021.7022,502.902,727,561.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-30Vivo Capital VIII, LLC10% Share HolderSell1,459.0022.1032,243.902,728,598.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-29Vivo Capital VIII, LLC10% Share HolderSell2,673.0022.2059,340.602,730,057.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2019-03-20Vivo Capital VIII, LLC10% Share HolderSell292,609.0022.256,510,550.252,732,730.00https://www.sec.gov/Archives/edgar/data/1658247/000161577419004434/0001615774-19-004434-index.htm
2018-07-20Vivo Capital VIII, LLC10% Share HolderBuy153,180.0020.733,175,421.40294,357.00https://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2020-04-17Vivo Capital VIII, LLC10% Share HolderSell10,265.0015.40158,081.00298,625.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2018-07-20Vivo Capital VIII, LLC10% Share HolderBuy51,686.0017.00878,662.003,025,339.00https://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2020-04-16Vivo Capital VIII, LLC10% Share HolderSell3,663.0015.2055,677.60308,890.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2019-01-225AM Ventures IV, L.P.10% Share HolderSell251,667.0021.885,505,215.633,107,642.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919003219/0001104659-19-003219-index.htm
2020-04-15Vivo Capital VIII, LLC10% Share HolderSell26,185.0015.50405,867.50312,553.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2018-07-205AM Ventures IV, L.P.10% Share HolderBuy110,400.0017.001,876,800.003,359,309.00https://www.sec.gov/Archives/edgar/data/1658247/000110465918046330/0001104659-18-046330-index.htm
2020-04-07Vivo Capital VIII, LLC10% Share HolderSell742.0014.2010,536.40338,738.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2020-04-03Vivo Capital VIII, LLC10% Share HolderSell36,400.0013.80502,320.00339,480.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2020-04-17PERCEPTIVE ADVISORS LLC10% Share HolderBuy1,071,428.0014.0014,999,992.003,659,381.00https://www.sec.gov/Archives/edgar/data/1658247/000089924320010940/0000899243-20-010940-index.htm
2020-03-09Vivo Capital VIII, LLC10% Share HolderSell48.0019.50936.00375,880.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020006030/0001213900-20-006030-index.htm
2020-02-10Vivo Capital VIII, LLC10% Share HolderSell200.0021.404,280.00375,928.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-07Vivo Capital VIII, LLC10% Share HolderSell157.0022.003,454.00376,128.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-04Vivo Capital VIII, LLC10% Share HolderSell357.0022.808,139.60376,285.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002831/0001213900-20-002831-index.htm
2020-01-31Vivo Capital VIII, LLC10% Share HolderSell143.0021.703,103.10376,642.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-30Vivo Capital VIII, LLC10% Share HolderSell201.0022.104,442.10376,785.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-29Vivo Capital VIII, LLC10% Share HolderSell369.0022.208,191.80376,986.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2019-03-20Vivo Capital VIII, LLC10% Share HolderSell40,407.0022.25899,055.75377,355.00https://www.sec.gov/Archives/edgar/data/1658247/000161577419004434/0001615774-19-004434-index.htm
2018-07-20Vivo Capital VIII, LLC10% Share HolderBuy7,137.0017.00121,329.00417,762.00https://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2020-07-16Richard Scott StruthersPresident & CEOSell17,500.0014.46253,107.75890,805.00https://www.sec.gov/Archives/edgar/data/1658247/000120919120042897/0001209191-20-042897-index.htm
2020-07-15Richard Scott StruthersPresident & CEOSell17,500.0015.30267,722.00908,305.00https://www.sec.gov/Archives/edgar/data/1658247/000120919120042897/0001209191-20-042897-index.htm
2019-06-215AM Ventures IV, L.P.InsiderSell10,000.0022.20222,000.0094,489.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919037468/0001104659-19-037468-index.htm
2020-04-28WENDALL WIERENGADirectorBuy25,329.000.7318,490.1799,846.00https://www.sec.gov/Archives/edgar/data/1658247/000120919120026196/0001209191-20-026196-index.htm